Rafael Holdings Inc. (RFL)
Market Closed
27 Jul, 20:00
NYSE NYSE Primary $
2. 28
+0.15
+7.0423%
$
79.75M Market Cap
17.6 P/E Ratio
- Div Yield
98,193 Volume
0 Eps
$ 2.13
Previous Close 
Want to track RFL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out.
Seekingalpha | 4 weeks ago
Oil prices fall as Hurricane Rafael expected to start weakening
Oil prices fell slightly on Friday as the risk that a hurricane in the Gulf of Mexico will affect U.S. oil and gas output declined while the market continues to weigh how President-elect Donald Trump's policies might affect supplies.
Reuters | 1 year ago
